Aslan Pharmaceuticals News

ASLNDelisted Stock  USD 0.60  0.03  4.76%   
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
over a year ago at benzinga.com         
Whats Going On With ASLAN Pharmaceuticals Stock Today?
benzinga news
over a year ago at marketwatch.com         
Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatment
marketwatch News
over a year ago at marketwatch.com         
Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatment
marketwatch News
over a year ago at globenewswire.com         
Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in A...
Macroaxis News: globenewswire.com
over a year ago at globenewswire.com         
ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD...
Macroaxis News: globenewswire.com
over a year ago at news.google.com         
Aslan Pharmaceuticals Ltd is down -1.05 percent in a Week, Should You Accumulate - InvestorsObserver
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
ASLAN Pharmaceuticals Limited Forecasted to Post Q1 2024 Earnings of Per Share
news
over a year ago at news.google.com         
Aslan signs 138.5M licensing deal with Zenyaku for atopic ... - BioWorld Online
Google News at Macroaxis
over a year ago at investing.com         
ASLAN Pharmaceuticals Reports Publication Highlighting Unique Mechanism of Action in the Treatment o...
Investing News at Macroaxis
over a year ago at globenewswire.com         
ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimabs Unique ...
Macroaxis News: globenewswire.com
over a year ago at finance.yahoo.com         
ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimabs Unique ...
Yahoo News
over a year ago at benzinga.com         
ASLAN Inks Licensing Deal With Zenyaku Kogyo To Commercialize Eblasakimab In Japan
benzinga news
over a year ago at finance.yahoo.com         
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development ...
Yahoo News
over a year ago at thelincolnianonline.com         
ASLAN Pharmaceuticals Limited Shares Sold by Tang Capital Management LLC
news
over a year ago at thelincolnianonline.com         
ASLAN Pharmaceuticals Limited Short Interest Update
news
Far too much social signal, news, headlines, and media speculation about Aslan Pharmaceuticals that are available to investors today. That information is available publicly through Aslan media outlets and privately through word of mouth or via Aslan internal channels. However, regardless of the origin, that massive amount of Aslan data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aslan Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aslan Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aslan Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aslan Pharmaceuticals alpha.

Aslan Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
ASLAN Pharmaceuticals Scheduled to Post Earnings on Friday - Defense World
04/25/2024
2
ASLAN Pharmaceuticals Buy Rating Reiterated at HC Wainwright - Defense World
05/06/2024
3
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
05/09/2024
4
Heres Why ASLAN Pharmaceuticals Could be Great Choice for a Bottom Fisher
06/04/2024
5
ASLAN Pharmaceuticals files to sell 61.9M ordinary shares for holders
06/12/2024
6
Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. , Heres Why Its a Buy Now - Yahoo New Zealand News
06/26/2024
7
Dow Jumps Over 200 Points NY Empire State Manufacturing Index Falls In July
07/15/2024
8
Why ASLAN Pharmaceuticals Shares Are Down 40
07/17/2024
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Consideration for investing in Aslan Stock

If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bonds Directory
Find actively traded corporate debentures issued by US companies
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.